Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price Expected to Rise, Cantor Fitzgerald Analyst Says

Regeneron Pharmaceuticals (NASDAQ:REGN) had its target price boosted by research analysts at Cantor Fitzgerald from $740.00 to $800.00 in a research report issued on Monday,Benzinga reports. The firm presently has an “overweight” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s target price indicates a potential upside of 5.38% from the company’s current price.

A number of other research analysts also recently issued reports on REGN. Wall Street Zen downgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday. Zacks Research raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 8th. Truist Financial lowered their target price on Regeneron Pharmaceuticals from $820.00 to $818.00 and set a “buy” rating for the company in a report on Monday. Wells Fargo & Company increased their price target on Regeneron Pharmaceuticals from $745.00 to $800.00 and gave the stock an “equal weight” rating in a research report on Monday. Finally, Canaccord Genuity Group boosted their price objective on Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the company a “buy” rating in a research report on Thursday, December 4th. Three research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $790.64.

Regeneron Pharmaceuticals Trading Up 0.6%

NASDAQ:REGN opened at $759.18 on Monday. The company has a market cap of $79.79 billion, a PE ratio of 18.27, a P/E/G ratio of 1.95 and a beta of 0.40. The business’s 50 day moving average is $757.70 and its two-hundred day moving average is $654.25. The company has a quick ratio of 4.22, a current ratio of 4.77 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals has a 52 week low of $476.49 and a 52 week high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.74 by $0.70. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The business had revenue of $3.88 billion for the quarter, compared to analyst estimates of $3.76 billion. During the same period in the prior year, the company posted $12.07 EPS. The business’s revenue was up 2.5% compared to the same quarter last year. On average, analysts predict that Regeneron Pharmaceuticals will post 35.92 EPS for the current year.

Insider Buying and Selling

In other news, VP Jason Pitofsky sold 431 shares of the business’s stock in a transaction on Friday, November 7th. The stock was sold at an average price of $651.43, for a total value of $280,766.33. Following the sale, the vice president owned 4,233 shares of the company’s stock, valued at approximately $2,757,503.19. The trade was a 9.24% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Bonnie L. Bassler sold 1,500 shares of the firm’s stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total value of $1,200,000.00. Following the transaction, the director directly owned 1,703 shares of the company’s stock, valued at $1,362,400. This represents a 46.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 7.02% of the stock is owned by company insiders.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Several hedge funds have recently made changes to their positions in the business. Osaic Holdings Inc. increased its holdings in shares of Regeneron Pharmaceuticals by 55.2% in the second quarter. Osaic Holdings Inc. now owns 17,068 shares of the biopharmaceutical company’s stock valued at $9,607,000 after buying an additional 6,073 shares in the last quarter. Robeco Institutional Asset Management B.V. raised its position in shares of Regeneron Pharmaceuticals by 153.4% during the third quarter. Robeco Institutional Asset Management B.V. now owns 120,884 shares of the biopharmaceutical company’s stock worth $67,969,000 after purchasing an additional 73,176 shares during the period. PGGM Investments lifted its holdings in shares of Regeneron Pharmaceuticals by 9.7% during the third quarter. PGGM Investments now owns 92,584 shares of the biopharmaceutical company’s stock valued at $52,057,000 after purchasing an additional 8,187 shares during the last quarter. Bellecapital International Ltd. boosted its position in shares of Regeneron Pharmaceuticals by 32.7% in the 2nd quarter. Bellecapital International Ltd. now owns 25,503 shares of the biopharmaceutical company’s stock valued at $13,389,000 after purchasing an additional 6,283 shares during the period. Finally, Rakuten Investment Management Inc. purchased a new position in Regeneron Pharmaceuticals in the 3rd quarter worth about $33,121,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Key Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: JPMorgan raised its price target to $950 and kept an “overweight” rating — a sizable increase that signals strong analyst conviction and adds meaningful upside to the stock. Benzinga
• Positive Sentiment: Oppenheimer reaffirmed an “outperform” rating and lifted its target to $865, reflecting continued confidence after Regeneron’s Q4 beat. Benzinga
• Positive Sentiment: Cantor Fitzgerald raised its target to $800 and maintained an “overweight” view, another vote of confidence supporting the rally. Benzinga
• Positive Sentiment: Wells Fargo lifted its price target to $800 (equal weight) — a modest boost that still reinforces momentum from the quarter. Benzinga
• Positive Sentiment: Regeneron highlighted new EYLEA HD presentations (QUASAR and ELARA results) at Angiogenesis 2026 — positive clinical data that can support the ophthalmology franchise outlook. EYLEA HD Presentations
• Positive Sentiment: Coverage roundup notes analysts revising forecasts after Regeneron’s upbeat Q4 results—consensus attention on the beat is lifting sentiment. Analyst Revisions After Q4
• Neutral Sentiment: Morgan Stanley nudged its target to $769 but kept an “equal weight” rating — a very small adjustment that signals limited near‑term upside from their view. TickerReport
• Neutral Sentiment: Market commentary pieces discuss Regeneron’s pipeline progress and valuation gap; useful context for longer‑term investors but not an immediate catalyst. Yahoo Finance
• Negative Sentiment: Truist trimmed its target slightly to $818 (still a “buy”) — a small downward tweak that may temper upside expectations from some investors. Benzinga

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.